Semaglutide — the key ingredient in Ozempic and Wegovy — had been in shortage since 2022. Now that supply has stabilized, state-licensed compounding pharmacies and physicians must stop selling ...

The blistering rally in Hims & Hers Health Inc. that’s captivated meme-stock traders has ground to a halt, setting up a ...

In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of ...

The Trump administration has started quietly rehiring some of the U.S. Food and Drug Administration employees it fired last week, according to nine agency sources, shortly after letting them go in a ...

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the ...

Makers of copycat weight-loss drugs and digital health companies that sell them are bracing for upheaval now that the Food ...

The FDA said weight-loss and diabetes drugs Wegovy and Ozempic are no longer on shortage list. The U.S. Food and Drug ...

The current state of health services highlights crucial sectors facing disruptions and developments, from US foreign aid freezes affecting disease control supply chains, to the FDA's actions on new ...

Hims & Hers Health (NYSE:HIMS) is set to report its earnings on Monday, Feb 24 after market close. HIMS stock plunged over 25 ...

The FDA has announced that the shortage of Wegovy and Ozempic, medications used for weight loss and diabetes management, is ...

Eli Lilly (LLY) and Novo Nordisk (NVO) to dominate as TD Cowen lifts 2030 sales forecast for GLP-1 class of obesity/ diabetes ...

The Food and Drug Administration announced Friday it had officially declared an end to the nationwide shortage of Ozempic and Wegovy, medications used for diabetes and weight loss. The agency first ...